Global cancer prevention and care efforts underwent major disruptions after 2020, driven by the ongoing effects of the COVID-19 pandemic and further exacerbated by persistent armed conflicts, changing health care funding priorities, and a cost-of-living crisis.
1,2 Between 2020 and 2022, the global Human Development Index (HDI), a composite measure of critical human development indicators such as life expectancy, education, and gross national income per capita, declined substantially for 2 consecutive years.
1 The consequences of these ongoing disruptions may disproportionately affect cancer care in certain regions and for individuals based on certain sociodemographic characteristics such as sex and age, resulting in disparities that can be assessed through the mortality to incidence ratio (MIR).
3-7 The MIR, for which higher values indicate higher case fatality and poor survival, has been used in the literature
3-7 and in government reports
8,9 in Australia
9 and the US
8 to assess cancer outcome equity.